132699-73-1

132699-73-1 structure

Name: [Leu31,Pro34]-Neuropeptide Y(human,rat)
Chemical Name: (4S)-4-[[2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxy-propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxy-propanoyl]amino]-4-oxo-butanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-[[(1S)-2-[[(1S)-2-[(2S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S,2S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-1-[[(1S,2R)-1-[[(1S)-1-[(2S)-2-[[(1S)-1-[[(1S)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-2-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methylsulfanyl-propyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]pyrrolidin-1-yl]-1-methyl-2-oxo-ethyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]amino]-5-oxo-pentanoic acid
CAS Number: 132699-73-1
Molecular Formula: C₁₈₉H₂₈₃N₅₄O₅₆S
Molecular Weight: 4240.67046
Catalog: Signaling Pathways GPCR/G Protein Neuropeptide Y Receptor
Create Date: 2018-06-28 18:46:28
Modify Date: 2024-01-20 20:04:52
[Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao inhibits Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake[1][2].

Name	(4S)-4-[[2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxy-propanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxy-propanoyl]amino]-4-oxo-butanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-[[(1S)-2-[[(1S)-2-[(2S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-2-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-2-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S)-2-[[(1S,2S)-1-[[(1S)-3-amino-1-[[(1S)-1-[[(1S)-1-[[(1S,2R)-1-[[(1S)-1-[(2S)-2-[[(1S)-1-[[(1S)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]pyrrolidine-1-carbonyl]-4-guanidino-butyl]carbamoyl]-2-hydroxy-propyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-oxo-propyl]carbamoyl]-2-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]carbamoyl]-3-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]amino]-1-(hydroxymethyl)-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]amino]-1-[(4-hydroxyphenyl)methyl]-2-oxo-ethyl]carbamoyl]-4-guanidino-butyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]-3-methylsulfanyl-propyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]carbamoyl]-3-carboxy-propyl]amino]-1-methyl-2-oxo-ethyl]carbamoyl]pyrrolidin-1-yl]-1-methyl-2-oxo-ethyl]amino]-1-(carboxymethyl)-2-oxo-ethyl]amino]-5-oxo-pentanoic acid
Synonyms	(Leu31,Pro34)-Neuropeptide Y (human, rat)

Description	[Leu31,Pro34]-Neuropeptide Y(human,rat) is a specific neuropeptide Y Y1 receptor agonist. [Leu31,Pro34]-Neuropeptide Y(human,rat) slao inhibits Y4, Y5. [Leu31,Pro34]-Neuropeptide Y(human,rat) can increase blood pressure in anesthetized rats and increases food intake[1][2].
Related Catalog	Research Areas >> Cardiovascular Disease Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> Neuropeptide Y Receptor
Target	NPY Y1 receptor NPY Y5 receptor NPY Y4 receptor
In Vitro	[Leu31,Pro34]-Neuropeptide Y(human,rat) has Ki values of 0.39 nM, 0.499 nM, 0.31 nM for Y1, Y4, Y5 in HEK cell lines. [Leu31,Pro34]-Neuropeptide Y(human,rat) has a Ki of >1000 for Y2 in HEK cell lines[2].
In Vivo	[Leu31,Pro34]-Neuropeptide Y(human,rat) (30 pmol; microinjected into paraventricular nucleus) increases food intake in the rats (350±400 g)[3].
References	[1]. J Fuhlendorff, et al. [Leu31, Pro34]neuropeptide Y: a specific Y₁ receptor agonist. Proc Natl Acad Sci U S A. 1990 Jan;87(1):182-6. [2]. K McCrea, et al. 2-36[K4,RYYSA(19-23)]PP a novel Y₅-receptor preferring ligand with strong stimulatory effect on food intake. Regul Pept. 2000 Feb 8;87(1-3):47-58. [3]. A Kask, et al. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y₁-selective antagonist BIBP3226. Br J Pharmacol. 1998 Aug;124(7):1507-15.

Molecular Formula	C₁₈₉H₂₈₃N₅₄O₅₆S
Molecular Weight	4240.67046
Storage condition	−20°C

WGK Germany	3

132699-73-1	302798-54-5
125580-28-1	178861-83-1
213779-13-6	131256-74-1
90880-35-6	150138-78-6
99575-89-0	123139-39-9
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
923504-10-3	6906-52-1
930439-75-1	951953-45-0
1018584-77-4	1375289-11-4